Zynex Announces 70% Order Growth and Increases Q3 2021 Adjusted EBITDA Estimate


2021-10-14 23:00:06 BioSpace


Zynex, Inc. , an innovative medical technology company specializing in manufacturing and selling non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced orders and an increased Adjusted EBITDA estimate for Q3 2021. Thomas Sandgaard, CEO of Zynex said: "Our order growth in Q3 remained strong at 70% year over year and 134% for the first three quarters of 2021. We are pleased with our continued revenue growth and the related profitability as we continue to leverage the sales investments we've made over the last couple years. Q3 2021 Adjusted EBITDA is by far the largest in company history and reaffirms our growth strategy. As our reps continue to get more efficient, our profitability will remain strong. We are confirming our previous revenue estimate for the third quarter of 2021 of between $34.5 and $36.0 million. Q3 2021 Adjusted EBITDA is now expected to come in between $9.0 and $10.0 million compared to the previous estimate of $5.0 to $6.0 million. The company's current full year 2021 revenue estimate is currently between $130.0 and $137.5 million. The revenue estimate is approximately 62% to 72% above last year's full year revenue of $80.1 million. The 2021 full year estimated Adjusted EBITDA is currently estimated between $16.5 to $21.5 million compared to 2020's full year Adjusted EBITDA of $13.7 million. The company will provide updated full year revenue and Adjusted EBITDA estimates with its Q3 2021 earnings release in late October. Our prescription-strength NexWave device is a healthy alternative to prescribing opioids as the first line of defense when treating pain. We continue to advocate for pain patients, and for physicians to prescribe our NexWave technology as the first line of defense in treating chronic and acute pain without side effects. We are dedicated to promoting our technology in an effort to remove patient addiction and other side effects from prescription opioids." About Zynex Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the Company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex also has a fluid monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com. Safe Harbor Statement This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, forecasts, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore you should not rely on any of these forward looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2020 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Contact: Zynex, Inc. (800) 495-6670 Investor Relations Contact: Amato and Partners, LLC Investor Relations Counsel admin@amatoandpartners.com multimedia:https://www.prnewswire.com/news-releases/zynex-announces-70-order-growth-and-increases-q3-2021-adjusted-ebitda-estimate-301399294.html
Zynex,Inc.是一家专门制造和销售用于疼痛管理、中风康复、心脏监测和神经诊断的无创医疗设备的创新医疗技术公司,今天宣布了2021年第三季度的订单和经调整的EBITDA估计。 Zynex首席执行官托马斯·桑德加德(Thomas Sandgaard)表示:“我们第三季度的订单增长保持强劲,同比增长70%,2021年前三季度增长134%。我们对收入的持续增长和相关盈利能力感到高兴,因为我们继续利用过去几年的销售投资。2021年第三季度调整后的EBITDA是公司历史上最大的,并重申了我们的增长战略。随着我们的代表继续提高效率,我们的盈利能力将保持强劲。 我们正在确认我们之前对2021年第三季度的收入估计在34.5至3600万美元之间。2021年第三季度经调整EBITDA现预计为9.0至1000万美元,而此前估计为5.0至600万美元。 该公司目前2021年全年收入估计在1.30.0至1.375亿美元之间。收入估计较去年全年收入8010万美元约高出62%至72%。2021年全年经调整EBITDA估计值目前估计介于16.5至2150万美元之间,而2020年全年经调整EBITDA为1370万美元。 该公司将于10月下旬发布2021年第三季度收益,提供更新的全年收入和调整后的EBITDA估计。 我们的处方强度NexWave设备是治疗疼痛时将阿片类药物作为第一道防线的健康替代方案。 我们继续倡导疼痛患者和医生将我们的NexWave技术作为治疗慢性和急性疼痛的第一道防线,而没有副作用。我们致力于推广我们的技术,以消除患者成瘾和处方阿片类药物的其他副作用。“ 关于Zynex Zynex成立于1996年,市场和销售自己设计的用于疼痛管理和康复的电疗医疗设备;以及该公司专有的NeuroMove设备,旨在帮助中风和脊髓损伤患者康复。Zynex也有一个液体监测器,用于医院和手术中心。欲了解更多信息,请访问:zynex.com。 安全港声明 本新闻稿包含1995年美国私人证券诉讼改革法案安全港条款含义范围内的前瞻性陈述。 前瞻性陈述既不是历史事实,也不是对未来业绩的保证。相反,它们仅基于我们目前对业务未来的信念、预期和假设、未来计划和战略、预测、预测、预期事件和趋势、经济和其他未来情况。由于前瞻性陈述与未来有关,它们受到难以预测的内在不确定性、风险和环境变化的影响,其中许多是我们无法控制的。我们的实际业绩和财务状况可能与前瞻性陈述中所显示的有重大差异。因此,你不应该依赖于这些前瞻性陈述中的任何一个。本公司对前瞻性陈述的完整性没有明示或暗示的陈述或保证,或在预测的情况下,对其可实现性或其所依据的假设的准确性和完整性没有明示或暗示的陈述或保证。可能导致实际结果与前瞻性陈述大不相同的因素包括,但不限于,新产品获得CE标志的需要,医生和医院对新产品以及现有产品的接受程度,拥有更大财力的更大竞争对手,跟上技术变革步伐的需要,我们对健康保险公司偿付我们产品的依赖、我们对第三方制造商按时生产我们产品的依赖和我们的规格、我们销售战略的实施包括强大的直接销售力量、新冠肺炎对全球经济的影响以及我们向证券交易委员会提交的文件中描述的其他风险,包括但不限于我们截至2020年12月31日止年度的10-K表格年度报告以及我们关于10-Q表格的季度报告和关于8-K表格的当前报告。 我们在本新闻稿中所做的任何前瞻性声明仅基于我们目前获得的信息,并仅限于发表之日。我们没有义务公开更新任何前瞻性声明,无论是书面的还是口头的,无论是由于新的信息、未来的发展还是其他原因而不时做出的。 联系人: Zynex公司。 (800)495-6670 投资者关系联系人: Amato和Partners有限责任公司 投资者关系顾问 admin@amatoandpartners.com 多媒体:https://www.prnewswire.com/news-releases/zynex-announces-70-order-growth-and-recrease-q3-2021-adjusted-ebitda-estimate-301399294.html